^
No biomarker
Esophageal Adenocarcinoma
nivolumab
Sensitive
:
A1
FDA - 3wk
NRG1 overexpression
Esophageal Squamous Cell Carcinoma
AV-203
Sensitive
:
C3
Am J Cancer Res - 3wk
No biomarker
Esophageal Squamous Cell Carcinoma
nivolumab
Sensitive
:
A1
PD-L1 expression
Esophageal Squamous Cell Carcinoma
pembrolizumab
Sensitive
:
A1
No biomarker
Esophageal Cancer
pembrolizumab
Sensitive
:
A1
No biomarker
Esophageal Cancer
nivolumab
Sensitive
:
A2
No biomarker
Esophageal Cancer
XP
Sensitive
:
A2
No biomarker
Esophageal Adenocarcinoma
ramucirumab
Sensitive
:
A2
No biomarker
Esophageal Cancer
docetaxel + irinotecan
Sensitive
:
A2
HER-2 positive
Esophageal Adenocarcinoma
trastuzumab
Sensitive
:
A2
HER-2 overexpression
Esophageal Adenocarcinoma
trastuzumab
Sensitive
:
A2
No biomarker
Esophageal Cancer
5-fluorouracil + irinotecan
Sensitive
:
A2
No biomarker
Esophageal Cancer
irinotecan
Sensitive
:
A2
No biomarker
Esophageal Cancer
CaT
Sensitive
:
A2
No biomarker
Esophageal Cancer
paclitaxel
Sensitive
:
A2
No biomarker
Esophageal Cancer
docetaxel
Sensitive
:
A2
No biomarker
Esophageal Cancer
IP
Sensitive
:
A2
No biomarker
Esophageal Cancer
cisplatin + paclitaxel
Sensitive
:
A2
No biomarker
Esophageal Cancer
cisplatin + 5-fluorouracil
Sensitive
:
A2
No biomarker
Esophageal Cancer
5-fluorouracil + oxaliplatin
Sensitive
:
A2
No biomarker
Esophageal Cancer
capecitabine + oxaliplatin
Sensitive
:
A2
NTRK3 fusion
Esophageal Cancer
larotrectinib
Sensitive
:
A2
NTRK2 fusion
Esophageal Cancer
larotrectinib
Sensitive
:
A2
NTRK1 fusion
Esophageal Cancer
larotrectinib
Sensitive
:
A2
NTRK3 fusion
Esophageal Cancer
entrectinib
Sensitive
:
A2
NTRK2 fusion
Esophageal Cancer
entrectinib
Sensitive
:
A2
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our